The whole study was divided into two major parts: (A) the 12-week, double-blind, randomized controlled, parallel omega-3 fatty acid monotherapy study in 60 patients with mild to moderate major depressive disorder. (B) The double-blind, randomized controlled, parallel omega-3 fatty acid add-on prevention study in 60 patients with major depressive disorder in recovery status. The goals of this study were to examine the therapeutic and recurrence prevention effects of omega-3 fatty acids on major depressive disorder.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
120
EPA 2.1 g/d+DHA 1.1 g/d
high oleic oil
China Medical University
Taichung, Taichung, Taiwan
HAMD
Time frame: W0 W2 W4 W8 W12
BDI
Time frame: W0 W2 W4 W8 W12
Adverse effects
Time frame: W0 W2 W4 W8 W12
Recurrence rate
Time frame: M0 M1 M2 M3 M4 M6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.